A recombinant fusion drug combining the Factor VIII protein with an FC antibody peptide to extend its lifetime in circulation has been approved for treating hemophilia A, the FDA said Friday.
Called Eloctate, the drug is made by Biogen Idec of Cambridge, Mass. The FDA said it was the first product of its kind to win its approval for the condition. Currently, hemophilia A is treated with recombinant Factor VIII or concentrates derived from blood donations.
Specific indications include control and prevention of bleeding episodes, management of bleeding during surgical procedures, and prophylaxis against bleeding episodes.
Read the full, original story: Hemophilia A Drug Gets FDA Nod
